Skip to main content
Premium Trial:

Request an Annual Quote

Correction: May 5, 2005


In last week’s Pharmacogenomics Reporter, the story “Roche Looks to Take Lead in Emerging 'Theranostics' Space With p53 AmpliChip,” erroneously reported that Roche is already using the p53 chip to stratify patients during clinical trials of Nutlin. In fact, the company is using the test to stratify patients in trials of other drugs in the company’s pipeline. The company still plans on forming partnerships with other pharma companies interested in the p53 chip.

Filed under

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.